Abstract

Recreational physical activity has been both positively and inversely associated with cancer risk for postmenopausal women, acting presumably through hormonal mechanisms. Relatively little is known about the effects of exercise on postmenopausal steroid hormone levels. The authors evaluated the association between recreational activity and plasma steroid hormones among 623 US healthy, postmenopausal women in the Nurses’ Health Study not using exogenous hormones at the time of blood draw (1989–1990). Participants self-reported recreational physical activity by questionnaire in 1986, 1988, and 1992. Plasma samples were assayed for estrogens, androgens, and sex hormone-binding globulin. Geometric mean hormone levels adjusted and not adjusted for body mass index were calculated. In general, estrogen and androgen levels were lower in the most- and the least-active women compared with those reporting moderate activity, suggesting a U-shaped relation. For example, estrone sulfate levels in quintiles 1–5 of metabolic equivalent task-hours were 197, 209, 222, 214, and 195 pg/mL, respectively. Tests for nonlinearity using polynomial regression were significant for several estrogens, androgens, and sex hormone-binding globulin (2-sided P ≤ 0.01). These results suggest the possibility of a nonlinear relation between recreational physical activity and hormone levels in postmenopausal women.

Recreational physical activity has been associated with reduced risk of postmenopausal breast (1–6) and endometrial (7–9) cancers. For ovarian cancer, results have been inconsistent (10), with some investigations observing a modest protective association (11–17) and others suggesting that physically active women may have a higher risk than less-active women (18–20). For example, a recent, large prospective study observed a significant 2-fold increase in ovarian cancer incidence in women reporting more than 4 hours per week of vigorous activity compared with those rarely engaging in vigorous activity (relative risk = 2.38, 95% confidence interval: 1.29, 4.38; P for trend < 0.01) (18).

Physical activity may influence risk of various cancers in part by altering sex steroid hormone levels (21), which have been positively associated with risk in some studies (22–25). However, relatively few studies have directly assessed the relation between physical activity and postmenopausal hormone levels (26–35). After menopause, circulating estrogens are almost exclusively produced through extraglandular aromatization of androgens, primarily androstenedione. Exercise may reduce estrogen levels by decreasing body fat and thereby reducing the conversion of androgens to estrogens. Levels of androgens, which are still produced by the ovaries in postmenopausal women, also may be affected (29). The extent to which body mass modifies this relation after menopause is unclear, although results from an exercise intervention trial suggest that the effect of exercise on sex steroid levels may be influenced by loss of body fat (28, 29). To address these questions, we assessed the association between participation in recreational physical activity and steroid hormone levels in a cross-sectional study of postmenopausal women, with special attention paid to the potential modifying effect of body mass.

MATERIALS AND METHODS

Study population

The Nurses’ Health Study is a cohort of 121,700 US female registered nurses who responded to a mailed questionnaire in 1976. Participants were 30–55 years of age at the time of the initial mailing and provided information on their medical history and health-related behaviors, such as use of oral contraceptives and smoking status. Cohort members have completed questionnaires every 2 years thereafter to update information on various risk factors and identify new diagnoses of cancer and other diseases. The protocol for this study was approved by the Human Research Committees at Brigham and Women's Hospital, Boston, Massachusetts.

In 1989–1990, we asked participants to provide a blood sample; samples were ultimately received from 32,826 women aged 43–69 years. Collection has been described in detail previously (36). Briefly, we provided participants with a kit containing blood-collection supplies and asked them to have their blood drawn and returned to us via overnight courier. Ice packs were supplied to keep samples cool during mailing. Participants completed a short questionnaire to record the day and time of collection, current body weight, and use of medications including hormone replacement therapy. Ninety-seven percent of samples were received by our laboratory within 26 hours of draw. Upon receipt, samples were centrifuged; were separated into plasma, red cell, and white cell components; and were archived at −130°C or colder in continuously monitored liquid nitrogen freezers.

Participants included in the present analysis were women chosen as controls for a nested case-control study of steroid hormone levels and breast cancer (22, 37). One to 2 controls were matched to each breast cancer case on the basis of age; menopausal status; use of postmenopausal hormones; and month, time of day, and fasting status at blood collection. Women eligible for the present analysis included all controls who were postmenopausal at blood collection (i.e., had reported no menstrual periods for at least 1 year), had not used postmenopausal hormones for at least 3 months prior to collection, and had not received a diagnosis of cancer other than nonmelanoma skin cancer as of May 31, 1998.

Assessment of physical activity

On Nurses’ Health Study questionnaires in 1986 and 1988, participants were asked to report the average amount of time each week they engaged in specific activities during the past year. These activities included jogging (i.e., slower than 10 minutes per mile (1 mile = 1.6 km)), running (i.e., 10 minutes per mile or faster), bicycling (including on a stationary machine), lap swimming, tennis, squash or racquet ball, aerobic activities (including calisthenics, aerobic dance, and rowing on a machine), and walking or hiking outdoors (including walking while playing golf). In addition, participants were asked about their usual walking pace and the number of flights of stairs they climbed daily. Similar questions were included on the 1992 Nurses’ Health Study questionnaire, along with new questions on low-intensity activities (yoga, stretching, toning) and other vigorous activities (lawn mowing). These questions have been validated in a similar population and are described in detail elsewhere (38). Briefly, in a sample of 153 women, the correlation was 0.79 (95% confidence interval: 0.64, 0.88) between physical activity scores calculated by physical activity questionnaire and a series of 4 past-week activity recalls completed over the previous year.

We evaluated the total amount of time per week participants reported engaging in physical activity. In addition, we calculated the total number of metabolic equivalent (MET)-hours of activity for each participant to account for the frequency, duration, and intensity of physical activity (39). To accomplish this goal, we multiplied the amount of time spent on each activity by its typical energy expenditure requirement in METs to calculate MET-hours for that activity. We then summed the contributions of each activity and divided participants into quintiles and deciles.

Assessment of covariates

We evaluated other factors that could potentially be associated with physical activity and/or steroid hormone levels. We assessed fasting status and time of day of blood collection, as well as body mass index (BMI, calculated as weight in kilograms/height in meters2), using the questionnaire completed at blood draw. We assessed other factors at approximately the time of blood draw using information provided on previous Nurses’ Health Study questionnaires, including age, age at menarche, parity and age at first birth, weight at age 18 years, age at menopause, history of tubal ligation and oral contraceptive use, and smoking status. We used a semiquantitative food frequency questionnaire administered as part of the main study questionnaire in 1990 to assess total energy and alcohol intake.

Hormone and sex hormone-binding globulin analyses

All plasma steroid hormones were analyzed in 4 batches. All batches of estrone, estradiol, androstenedione, testosterone, dehydroepiandosterone (DHEA), and dehydroepiandosterone sulfate (DHEAS), along with the last 3 batches of estrone sulfate, were assayed at Quest Diagnostic's Nichols Institute (San Juan Capistrano, California). The first batch of estrone sulfate and first 2 batches of sex hormone-binding globulin (SHBG) were assayed at the Longcope Steroid Radioimmunoassay Laboratory at the University of Massachusetts Medical Center (Worcester, Massachusetts). The remaining batches of SHBG were assayed by the Massachusetts General Hospital's Reproductive Endocrinology Unit Laboratory (Boston, Massachusetts).

Methods used for hormone assays have been described in detail previously (22, 37). Briefly, samples were extracted with a mixture of hexane and ethyl acetate (4:1) and were applied to a celite column. Steroids were then eluted from the column (celite in ethylene glycol), and the fractions were analyzed by radioimmunoassay (40–44). DHEAS was assayed by radioimmunoassay without a prior separation step (45). Estrone sulfate was first extracted from plasma with an organic solvent and was then analyzed by chromatography and radioimmunoassay (46). Levels of free estradiol and bioavailable estradiol (i.e., estradiol that is either free or loosely bound to albumin) were directly measured in a subset of samples. SHBG was measured with an immunoradiometric kit from FARMOS Diagnostica (Orion Corp., Turku, Finland) in the Longcope laboratory and with the AxSYM Immunoassay system (Abbott Diagnostics, Chicago, Illinois) in the Massachusetts General Hospital Reproductive Endocrinology Unit laboratory.

To allow for assessment of batch-to-batch variation and laboratory precision, we randomly distributed blinded quality control samples (equivalent to 10% of replicates) along with all analytic samples. Mean within-batch coefficients of variation ranged from 6% for DHEAS to 13.6% for DHEA (22, 37).

Statistical analysis

All statistical analyses were conducted by using SAS software (SAS Institute, Inc., Cary, North Carolina). We evaluated the distribution of each steroid hormone and identified outliers, defined as women whose levels were greater than the absolute value of the 75th percentile plus 3 times the interquartile range; between 2 (SHBG and androstenedione) and 14 (estrone sulfate) women were excluded from analyses of each hormone.

For each type of physical activity we assessed, for our primary analysis we averaged each woman's level of participation in 1986 and 1988 to provide a more stable assessment of activity participation in the 1–4 years prior to blood collection. We estimated geometric least squares mean hormone levels across categories of average of physical activity level by regressing the natural log of hormone levels on potential confounders, then adding the mean log hormone levels to the average of the residuals and exponentiating this value. The final results were the predicted hormonal levels at the reference value for the confounders. All P values presented are 2-sided.

To assess the influence of body mass on the activity-hormone relation, we calculated geometric mean hormone levels both adjusting and not adjusting for BMI at the time of blood collection. We evaluated linear trends across categories using multivariable linear regression and Wald tests. Because preliminary results suggested the possibility of a U-shaped relation between physical activity and hormone levels, we conducted a posteriori evaluation of nonlinearity using polynomial regression. We first regressed continuous natural log (ln) MET-hours per week of physical activity on ln hormone levels. We then added a second-order term (i.e., the square of ln MET-hours of activity) to the model and performed an F test to ascertain whether inclusion of this term explained more of the variation in ln hormone levels than expected because of chance alone.

In addition, we conducted subanalyses stratified by BMI at the time of blood collection (<23, 23–<27, ≥27 kg/m2). Our decision to use nonstandard categories of BMI was based largely on sample size and power considerations; very few participants had a BMI ≥30 kg/m2, and parameter estimates using this category cutpoint were unstable. We also stratified by weight change between 1988 and date of blood draw (weight loss, no change/weight gain), with weight change measured by subtracting weight reported in 1988 from weight reported on the questionnaire administered at blood collection. Analyses were repeated by using physical activity as assessed in 1988 only and by the average of activity in 1988 and 1992. Furthermore, we assessed the effect of average activity in 1988–1992 after stratifying by change in physical activity between 1988 and 1992 (increase of ≥1 quintile of METs in 1992, no change, decreased by ≥1 quintile). Finally, we evaluated these associations among women who had not reported an oophorectomy prior to blood draw.

RESULTS

We limited our main analysis to the 623 women who had both complete physical activity assessments in 1986 and 1988 and available plasma samples. Characteristics of study members in quintiles 1, 3, and 5 of MET-hours per week of activity are presented in Table 1. Distribution of most characteristics varied by level of physical activity. The mean age of study participants was approximately 62 years (range, 46–69). Mean BMI at the time of blood draw ranged from 24.8 kg/m2 for women reporting the highest level of physical activity to 27.4 kg/m2 for those reporting the lowest. Current smoking was reported by 8.6% of participants in quintile 5 compared with 20.2% of women in quintile 1.

Table 1.

Age-standardized Characteristics of 623 Members of the Nurses’ Health Study Included in a Study of Physical Activity and Steroid Hormone Levels, by Quintile of MET-Hours per Week,a United States, 1986–1990

Characteristicb MET-Hours per Week (No. of Participants)
 
Quintile 1 (n = 123)
 
Quintile 3 (n = 129)
 
Quintile 5 (n = 130)
 
Mean (SE) Mean (SE) Mean (SE) 
Age, years 61.4 (4.2)  62.0 (4.4)  61.6 (5.2)  
BMI at blood draw, kg/m2 27.4 (0.4)  26.2 (0.4)  24.8 (0.4)  
BMI at age 18 years, kg/m2 21.3 (0.4)  21.3 (0.4)  20.7 (0.4)  
Change in weight since age 18 years, kg 16.4 (1.4)  13.4 (1.4)  11.0 (1.3)  
Age at menarche, years 12.7 (0.2)  12.4 (0.2)  12.5 (0.2)  
Parity: no. of pregnancies lasting ≥6 months 3.8 (0.2)  3.2 (0.2)  3.0 (0.2)  
Age at first birth, yearsc 25.2 (0.3)  25.1 (0.3)  25.5 (0.3)  
Age at menopause, yearsd 50.2 (0.4)  50.2 (0.3)  49.7 (0.3)  
Total energy intake in 1990, kcal/daye 1,766 (45)  1,754 (43)  1,727 (43)  
Alcohol intake in 1990, g/daye 5.2 (1.0)  5.1 (0.9)  5.5 (0.9)  
Oophorectomy before blood collection  33.6  25.9  26.0 
Current smoker in 1990  20.2  12.9  8.6 
Former smoker in 1990  38.3  33.7  49.5 
History of tubal ligation  18.3  10.8  13.4 
History of oral contraceptive use  29.6  39.5  32.0 
Characteristicb MET-Hours per Week (No. of Participants)
 
Quintile 1 (n = 123)
 
Quintile 3 (n = 129)
 
Quintile 5 (n = 130)
 
Mean (SE) Mean (SE) Mean (SE) 
Age, years 61.4 (4.2)  62.0 (4.4)  61.6 (5.2)  
BMI at blood draw, kg/m2 27.4 (0.4)  26.2 (0.4)  24.8 (0.4)  
BMI at age 18 years, kg/m2 21.3 (0.4)  21.3 (0.4)  20.7 (0.4)  
Change in weight since age 18 years, kg 16.4 (1.4)  13.4 (1.4)  11.0 (1.3)  
Age at menarche, years 12.7 (0.2)  12.4 (0.2)  12.5 (0.2)  
Parity: no. of pregnancies lasting ≥6 months 3.8 (0.2)  3.2 (0.2)  3.0 (0.2)  
Age at first birth, yearsc 25.2 (0.3)  25.1 (0.3)  25.5 (0.3)  
Age at menopause, yearsd 50.2 (0.4)  50.2 (0.3)  49.7 (0.3)  
Total energy intake in 1990, kcal/daye 1,766 (45)  1,754 (43)  1,727 (43)  
Alcohol intake in 1990, g/daye 5.2 (1.0)  5.1 (0.9)  5.5 (0.9)  
Oophorectomy before blood collection  33.6  25.9  26.0 
Current smoker in 1990  20.2  12.9  8.6 
Former smoker in 1990  38.3  33.7  49.5 
History of tubal ligation  18.3  10.8  13.4 
History of oral contraceptive use  29.6  39.5  32.0 

Abbreviations: BMI, body mass index; MET, metabolic equivalent; SE, standard error.

a

Medians for quintiles 1, 3, and 5 are 1.7, 9.3, and 34.3 MET-hours per week, respectively.

b

All characteristics, except for age, were standardized to the age distribution of the study population in 1990; arithmetic mean and standard deviation are presented for age.

c

Among parous women.

d

Among women experiencing a natural menopause.

e

Among women who completed a semiquantitative food frequency questionnaire in 1990.

The number of plasma samples available for analysis varied between hormones, ranging from 417 for bioavailable estradiol to 607 for DHEAS (Table 2). Measured hormone levels were consistent with those expected for postmenopausal women not using hormone therapy.

Table 2.

Distribution of Plasma Hormone Levels Among Members of the Nurses’ Health Study Included in a Study of Physical Activity and Steroid Hormone Levels, United States, 1986–1990

Hormone No. of Participants Median 10th–90th Percentile 
Estradiol, pg/mL 605 6.0 4–13 
Bioavailable estradiol, pg/mL 417 1.6 0.6–4.2 
Free estradiol, pg/mL 418 0.10 0.06–0.23 
Estrone, pg/mL 599 24 13–43 
Estrone sulfate, pg/mL 588 206 99–513 
Androstenedione, ng/dL 603 57 29–108 
Testosterone, ng/dL 604 22 11–39 
DHEA, ng/dL 570 210 88–420 
DHEAS, μg/dL 607 84 32–174 
SHBG, nmol/L 603 47 22–83 
Hormone No. of Participants Median 10th–90th Percentile 
Estradiol, pg/mL 605 6.0 4–13 
Bioavailable estradiol, pg/mL 417 1.6 0.6–4.2 
Free estradiol, pg/mL 418 0.10 0.06–0.23 
Estrone, pg/mL 599 24 13–43 
Estrone sulfate, pg/mL 588 206 99–513 
Androstenedione, ng/dL 603 57 29–108 
Testosterone, ng/dL 604 22 11–39 
DHEA, ng/dL 570 210 88–420 
DHEAS, μg/dL 607 84 32–174 
SHBG, nmol/L 603 47 22–83 

Abbreviations: DHEA, dehydroepiandosterone; DHEAS, dehydroepiandosterone sulfate; SHBG, sex hormone-binding globulin.

Geometric mean hormone and SHBG levels by hours per week of physical activity are presented in Table 3. Before adjustment for BMI at blood collection, estradiol, bioavailable estradiol, and free estradiol appeared to be inversely related to physical activity levels (P = 0.002–0.02). In contrast, SHBG was positively related to activity level (P = 0.002). Of the androgens evaluated, we did not observe substantial evidence of a linear relation with activity.

Table 3.

Estimated Geometric Mean Hormone Levels and 95% Confidence Intervals by Average Hours per Week of Physical Activity, Nurses’ Health Study, United States, 1986–1988

 Hours per Week of Physical Activity (Range of No. of Samples)a
 
P for Trendb 
 <1 (116–174)
 
1–<2 (78–123)
 
2–<4 (84–130)
 
4–<7 (82–113)
 
≥7 (51–76)
 
 Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI 
Estradiol, pg/mL            
    Multivariablec 7.2 5.5, 9.5 7.3 5.6, 9.6 6.5 4.9, 8.5 6.7 5.1, 8.9 6.4 4.8, 8.5 0.02 
    Multivariable with BMId 6.3 5.0, 8.1 6.5 5.1, 8.3 6.1 4.7, 7.7 6.5 5.0, 8.3 6.2 4.8, 8.0 0.37 
Bioavailable estradiol, pg/mL            
    Multivariablec 2.0 1.2, 3.3 1.9 1.1, 3.2 1.7 1.0, 2.8 1.6 0.9, 2.7 1.5 0.9, 2.6 0.006 
    Multivariable with BMId 1.5 1.0, 2.3 1.5 0.09, 2.3 1.3 0.9, 2.1 1.4 0.9, 2.2 1.3 0.8, 2.1 0.20 
Free estradiol, pg/mL            
    Multivariablec 0.14 0.10, 0.20 0.13 0.09, 0.19 0.12 0.09, 0.17 0.12 0.09, 0.18 0.12 0.08, 0.17 0.002 
    Multivariable with BMId 0.12 0.09, 0.16 0.12 0.08, 0.16 0.11 0.08, 0.15 0.11 0.08, 0.16 0.11 0.08, 0.15 0.06 
Estrone, pg/mL            
    Multivariablec 28 21, 26 29 22, 37 26 20, 34 27 21, 36 26 20, 34 0.43 
    Multivariable with BMId 26 20, 33 27 21, 35 25 20, 32 27 21, 35 26 20, 34 0.81 
Estrone sulfate, pg/mL            
    Multivariablec 218 163, 292 238 177, 320 231 171, 311 206 152, 279 199 146, 271 0.19 
    Multivariable with BMId 198 149, 261 216 163, 286 219 164, 292 202 151, 269 198 148, 266 0.91 
Androstenedione, ng/dL            
    Multivariablec 55 42, 73 56 43, 74 51 39, 68 55 42, 73 51 39, 68 0.17 
    Multivariable with BMId 55 42, 73 56 42, 74 52 39, 68 56 42, 74 52 39, 69 0.21 
Testosterone, ng/dL            
    Multivariablec 18 14, 23 19 15, 24 18 14, 23 19 14, 24 17 13, 23 0.46 
    Multivariable with BMId 18 14, 23 19 15, 25 18 14, 23 19 15, 25 18 14, 24 0.55 
DHEA, ng/dL            
    Multivariablec 127 89, 182 134 94, 191 135 94, 194 149 103, 215 128 89, 186 0.66 
    Multivariable with BMId 124 87, 177 130 91, 186 131 91, 188 145 100, 210 124 85, 181 0.63 
DHEAS, μg/dL            
    Multivariablec 66 47, 92 69 49, 96 68 49, 96 74 52, 105 67 47, 95 0.63 
    Multivariable with BMId 63 45, 89 65 46, 92 65 46, 92 72 51, 102 65 46, 92 0.46 
SHBG, nmol/L            
    Multivariablec 37 30, 45 38 31, 47 43 35, 53 44 35, 54 44 35, 55 0.002 
    Multivariable with BMId 42 34, 50 43 35, 52 46 38, 56 46 37, 56 45 37, 56 0.08 
 Hours per Week of Physical Activity (Range of No. of Samples)a
 
P for Trendb 
 <1 (116–174)
 
1–<2 (78–123)
 
2–<4 (84–130)
 
4–<7 (82–113)
 
≥7 (51–76)
 
 Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI 
Estradiol, pg/mL            
    Multivariablec 7.2 5.5, 9.5 7.3 5.6, 9.6 6.5 4.9, 8.5 6.7 5.1, 8.9 6.4 4.8, 8.5 0.02 
    Multivariable with BMId 6.3 5.0, 8.1 6.5 5.1, 8.3 6.1 4.7, 7.7 6.5 5.0, 8.3 6.2 4.8, 8.0 0.37 
Bioavailable estradiol, pg/mL            
    Multivariablec 2.0 1.2, 3.3 1.9 1.1, 3.2 1.7 1.0, 2.8 1.6 0.9, 2.7 1.5 0.9, 2.6 0.006 
    Multivariable with BMId 1.5 1.0, 2.3 1.5 0.09, 2.3 1.3 0.9, 2.1 1.4 0.9, 2.2 1.3 0.8, 2.1 0.20 
Free estradiol, pg/mL            
    Multivariablec 0.14 0.10, 0.20 0.13 0.09, 0.19 0.12 0.09, 0.17 0.12 0.09, 0.18 0.12 0.08, 0.17 0.002 
    Multivariable with BMId 0.12 0.09, 0.16 0.12 0.08, 0.16 0.11 0.08, 0.15 0.11 0.08, 0.16 0.11 0.08, 0.15 0.06 
Estrone, pg/mL            
    Multivariablec 28 21, 26 29 22, 37 26 20, 34 27 21, 36 26 20, 34 0.43 
    Multivariable with BMId 26 20, 33 27 21, 35 25 20, 32 27 21, 35 26 20, 34 0.81 
Estrone sulfate, pg/mL            
    Multivariablec 218 163, 292 238 177, 320 231 171, 311 206 152, 279 199 146, 271 0.19 
    Multivariable with BMId 198 149, 261 216 163, 286 219 164, 292 202 151, 269 198 148, 266 0.91 
Androstenedione, ng/dL            
    Multivariablec 55 42, 73 56 43, 74 51 39, 68 55 42, 73 51 39, 68 0.17 
    Multivariable with BMId 55 42, 73 56 42, 74 52 39, 68 56 42, 74 52 39, 69 0.21 
Testosterone, ng/dL            
    Multivariablec 18 14, 23 19 15, 24 18 14, 23 19 14, 24 17 13, 23 0.46 
    Multivariable with BMId 18 14, 23 19 15, 25 18 14, 23 19 15, 25 18 14, 24 0.55 
DHEA, ng/dL            
    Multivariablec 127 89, 182 134 94, 191 135 94, 194 149 103, 215 128 89, 186 0.66 
    Multivariable with BMId 124 87, 177 130 91, 186 131 91, 188 145 100, 210 124 85, 181 0.63 
DHEAS, μg/dL            
    Multivariablec 66 47, 92 69 49, 96 68 49, 96 74 52, 105 67 47, 95 0.63 
    Multivariable with BMId 63 45, 89 65 46, 92 65 46, 92 72 51, 102 65 46, 92 0.46 
SHBG, nmol/L            
    Multivariablec 37 30, 45 38 31, 47 43 35, 53 44 35, 54 44 35, 55 0.002 
    Multivariable with BMId 42 34, 50 43 35, 52 46 38, 56 46 37, 56 45 37, 56 0.08 

Abbreviations: BMI, body mass index; CI, confidence interval; DHEA, dehydroepiandosterone; DHEAS, dehydroepiandosterone sulfate; SHBG, sex hormone-binding globulin.

a

Number of samples included in analysis varied by hormone, ranging from 417 for bioavailable estradiol to 607 for DHEAS.

b

P values are 2-sided.

c

Hormone levels were adjusted for age (≤55, 56–60, 61–65, >65 years), batch (4 batches), time of blood collection (7–9 AM, 10 AM–12 PM, 1–3 PM, 4 PM–6 AM, missing), fasting status (0–3, 4–7, 8–11, 12–24 hours since last meal), age at menarche (<12, 12, 13, ≥14 years), parity × age at first birth (nulliparous, 1–2 births and <25 years, 1–2 births and ≥25 years, 3–8 births and <25 years, 3–8 births and ≥25 years), age at menopause (<45, 45–52, ≥53 years), smoking status (never smoker, former smoker, current smoker and 1–14 cigarettes per day, current smoker and ≥15 cigarettes per day), history of tubal ligation (no, yes), history of bilateral oophorectomy (no, yes), and alcohol intake (0, 0.1–4.9, 5–14.9, ≥15 g per day).

d

Hormone levels were adjusted for factors included in the multivariable model plus BMI (<21, 21–<23, 23–<25, 25–<30, ≥30 kg/m2).

We observed strong correlations between BMI and estrogen and SHBG levels. Pearson correlation coefficients ranged from 0.32 (P < 0.0001) for estrone sulfate to 0.59 (P < 0.0001) for bioavailable estradiol. SHBG was inversely related to BMI (r = −0.38; P < 0.0001). In contrast, androgen levels were not significantly correlated with BMI (range of r, −0.006 to 0.03). Physical activity was significantly inversely correlated with BMI, with the strongest correlations observed for activity measured as MET-hours per week (r = −0.17; P < 0.0001). After further adjustment for BMI, estradiol and SHBG levels were no longer linearly associated with hours per week of activity (Table 3). The relation between androgen levels and physical activity was largely unchanged after adjustment for BMI.

In analyses not adjusting for BMI, we observed some evidence of a linear relation between hormone levels and MET-hours per week of activity (Table 4), although adjustment for BMI attenuated these associations. For all of the hormones evaluated, levels tended to be lowest in women reporting the highest level of activity (i.e., quintile 5) compared with those reporting moderate levels (i.e., quintiles 2–4). For example, for estradiol, mean levels over increasing quintiles were 6.4, 6.9, 6.4, 6.8, and 6.1 pg/mL, respectively. To assess nonlinearity, we fit linear and polynomial regression models and assessed model fit (Table 5). F-test results indicated that model fit significantly improved with the addition of a second-order term to the base linear regression model for estradiol, free estradiol, bioavailable estradiol, estrone, DHEA, androstenedione, and SHBG (range of P = 0.0002 for estradiol to P = 0.007 for free estradiol).

Table 4.

Estimated Geometric Mean Hormone Levels and 95% Confidence Intervals by Average MET-Hours per Week of Physical Activity, Nurses’ Health Study, United States, 1986–1988

 Quintilea of MET-Hours per Week (Quintile Median)b
 
P for Trendc 
 1 (1.7)
 
2 (4.4)
 
3 (9.3)
 
4 (19.0)
 
5 (34.3)
 
 Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI 
Estradiol, pg/mL            
    Multivariabled 7.4 5.6, 9.7 7.9 6.0, 10.5 7.1 5.5, 9.3 7.2 5.5, 9.5 6.3 4.8, 8.3 0.0006 
    Multivariable with BMIe 6.4 5.1, 8.1 6.9 5.4, 8.9 6.4 5.1, 8.2 6.8 5.3, 8.7 6.1 4.8, 7.8 0.06 
Bioavailable estradiol, pg/mL            
    Multivariabled 2.0 1.2, 3.4 2.5 1.5, 4.2 1.9 1.1, 3.1 1.8 1.1, 3.1 1.6 0.9, 2.6 0.0006 
    Multivariable with BMIe 1.5 0.09, 2.3 1.8 1.1, 2.8 1.5 0.9, 2.3 1.5 1.0, 2.4 1.4 0.9, 2.1 0.06 
Free estradiol, pg/mL            
    Multivariabled 0.15 0.11, 0.21 0.15 0.10, 0.21 0.13 0.09, 0.18 0.13 0.09, 0.19 0.12 0.08, 0.16 <0.0001 
    Multivariable with BMIe 0.12 0.09, 0.17 0.13 0.09, 0.17 0.12 0.08, 0.16 0.12 0.09, 0.16 0.11 0.08, 0.15 0.007 
Estrone, pg/mL            
    Multivariabled 28 22, 37 29 22, 39 29 22, 38 27 21, 36 25 19, 33 0.02 
    Multivariable with BMIe 26 20, 33 28 21, 36 28 21, 36 27 21, 35 25 20, 32 0.27 
Estrone sulfate, pg/mL            
    Multivariabled 222 165, 300 233 171, 317 243 181, 325 223 164, 304 196 146, 263 0.03 
    Multivariable with BMIe 197 148, 263 209 156, 281 222 168, 294 214 159, 286 195 148, 258 0.42 
Androstenedione, ng/dL            
    Multivariabled 55 42, 73 63 48, 83 55 42, 72 57 43, 75 52 40, 68 0.02 
    Multivariable with BMIe 55 42, 73 63 47, 84 55 42, 73 58 44, 77 52 40, 68 0.02 
Testosterone, ng/dL            
    Multivariabled 18 14, 23 20 15, 25 19 15, 24 20 15, 26 17 13, 22 0.06 
    Multivariable with BMIe 18 14, 23 20 15, 26 19 15, 24 20 16, 27 17 14, 22 0.08 
DHEA, ng/dL            
    Multivariabled 122 85, 175 143 99, 207 135 95, 192 150 104, 215 130 91, 186 0.58 
    Multivariable with BMIe 119 119, 83 140 96, 203 131 92, 187 146 101, 211 126 88, 180 0.60 
DHEAS, μg/dL            
    Multivariabled 64 46, 91 74 52, 105 68 49, 95 74 52, 104 68 49, 96 0.83 
    Multivariable with BMIe 62 44, 87 71 50, 101 65 46, 91 71 50, 101 66 47, 93 0.92 
SHBG, nmol/L            
    Multivariabled 35 28, 43 36 29, 45 40 33, 50 40 32, 50 45 36, 55 0.0005 
    Multivariable with BMIe 40 33, 49 41 34, 51 45 37, 54 43 35, 53 46 38, 56 0.06 
 Quintilea of MET-Hours per Week (Quintile Median)b
 
P for Trendc 
 1 (1.7)
 
2 (4.4)
 
3 (9.3)
 
4 (19.0)
 
5 (34.3)
 
 Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI Hormone Level 95% CI 
Estradiol, pg/mL            
    Multivariabled 7.4 5.6, 9.7 7.9 6.0, 10.5 7.1 5.5, 9.3 7.2 5.5, 9.5 6.3 4.8, 8.3 0.0006 
    Multivariable with BMIe 6.4 5.1, 8.1 6.9 5.4, 8.9 6.4 5.1, 8.2 6.8 5.3, 8.7 6.1 4.8, 7.8 0.06 
Bioavailable estradiol, pg/mL            
    Multivariabled 2.0 1.2, 3.4 2.5 1.5, 4.2 1.9 1.1, 3.1 1.8 1.1, 3.1 1.6 0.9, 2.6 0.0006 
    Multivariable with BMIe 1.5 0.09, 2.3 1.8 1.1, 2.8 1.5 0.9, 2.3 1.5 1.0, 2.4 1.4 0.9, 2.1 0.06 
Free estradiol, pg/mL            
    Multivariabled 0.15 0.11, 0.21 0.15 0.10, 0.21 0.13 0.09, 0.18 0.13 0.09, 0.19 0.12 0.08, 0.16 <0.0001 
    Multivariable with BMIe 0.12 0.09, 0.17 0.13 0.09, 0.17 0.12 0.08, 0.16 0.12 0.09, 0.16 0.11 0.08, 0.15 0.007 
Estrone, pg/mL            
    Multivariabled 28 22, 37 29 22, 39 29 22, 38 27 21, 36 25 19, 33 0.02 
    Multivariable with BMIe 26 20, 33 28 21, 36 28 21, 36 27 21, 35 25 20, 32 0.27 
Estrone sulfate, pg/mL            
    Multivariabled 222 165, 300 233 171, 317 243 181, 325 223 164, 304 196 146, 263 0.03 
    Multivariable with BMIe 197 148, 263 209 156, 281 222 168, 294 214 159, 286 195 148, 258 0.42 
Androstenedione, ng/dL            
    Multivariabled 55 42, 73 63 48, 83 55 42, 72 57 43, 75 52 40, 68 0.02 
    Multivariable with BMIe 55 42, 73 63 47, 84 55 42, 73 58 44, 77 52 40, 68 0.02 
Testosterone, ng/dL            
    Multivariabled 18 14, 23 20 15, 25 19 15, 24 20 15, 26 17 13, 22 0.06 
    Multivariable with BMIe 18 14, 23 20 15, 26 19 15, 24 20 16, 27 17 14, 22 0.08 
DHEA, ng/dL            
    Multivariabled 122 85, 175 143 99, 207 135 95, 192 150 104, 215 130 91, 186 0.58 
    Multivariable with BMIe 119 119, 83 140 96, 203 131 92, 187 146 101, 211 126 88, 180 0.60 
DHEAS, μg/dL            
    Multivariabled 64 46, 91 74 52, 105 68 49, 95 74 52, 104 68 49, 96 0.83 
    Multivariable with BMIe 62 44, 87 71 50, 101 65 46, 91 71 50, 101 66 47, 93 0.92 
SHBG, nmol/L            
    Multivariabled 35 28, 43 36 29, 45 40 33, 50 40 32, 50 45 36, 55 0.0005 
    Multivariable with BMIe 40 33, 49 41 34, 51 45 37, 54 43 35, 53 46 38, 56 0.06 

Abbreviations: BMI, body mass index; CI, confidence interval; DHEA, dehydroepiandosterone; DHEAS, dehydroepiandosterone sulfate; MET, metabolic equivalent; SHBG, sex hormone-binding globulin.

a

Range of numbers for quintiles 1–5 are 81–121, 78–117, 83–125, 81–121, and 89–128, respectively.

b

Number of samples included in analysis varied by hormone, ranging from 417 for bioavailable estradiol to 605 for DHEAS.

c

P values are 2-sided.

d

Hormone levels were adjusted for age, batch, time of blood collection, fasting status, age at menarche, parity × age at first birth, age at menopause, smoking status, history of tubal ligation, history of bilateral oophorectomy, and alcohol intake. Refer to Table 3, footnote c, for variable categories.

e

Hormone levels were adjusted for factors included in the multivariable model plus BMI (<21, 21–<23, 23–<25, 25–<30, ≥30 kg/m2).

Table 5.

Comparison of Beta Coefficients and Model Fit for Linear and Polynomial Regression Models of Average Continuous Natural Log (ln) MET-Hours per Week of Physical Activity, 1986–1988, and ln Steroid Hormone Levels, Nurses’ Health Study, United Statesa

Hormone β1 P1)b β2 P2)b F P(F)b 
Estradiol, pg/mL       
    Linear modelc −0.03264 0.04     
    Polynomial modeld 0.05917 0.10 −0.02724 0.004 8.55 0.0002 
Bioavailable estradiol, pg/mL       
    Linear modelc −0.07197 0.01     
    Polynomial modeld 0.08409 0.21 −0.04466 0.01 6.96 0.001 
Free estradiol, pg/mL       
    Linear modelc −0.06346 0.001     
    Polynomial modeld 0.02421 0.58 −0.02515 0.03 4.99 0.007 
Estrone, pg/mL       
    Linear modelc −0.01233 0.45     
    Polynomial modeld 0.08243 0.03 −0.0276 0.005 8.21 0.0003 
Estrone sulfate, pg/mL       
    Linear modelc −0.02312 0.26     
    Polynomial modeld 0.03107 0.51 −0.01564 0.20 1.62 0.20 
Androstenedione, ng/dL       
    Linear modelc −0.01852 0.29     
    Polynomial modeld 0.07898 0.05 −0.02844 0.006 7.72 0.0004 
Testosterone, ng/dL       
    Linear modelc −0.01282 0.43     
    Polynomial modeld 0.03697 0.32 −0.01454 0.14 2.29 0.11 
DHEA, ng/dL       
    Linear modelc 0.01784 0.41     
    Polynomial modeld 0.13066 0.007 −0.03331 0.009 7.07 0.0009 
DHEAS, μg/dL       
    Linear modelc 0.01664 0.45     
    Polynomial modeld 0.0908 0.07 −0.02144 0.10 2.71 0.07 
SHBG, nmol/L       
    Linear modelc 0.04508 0.007     
    Polynomial modeld −0.03848 0.29 0.02478 0.01 6.82 0.001 
Hormone β1 P1)b β2 P2)b F P(F)b 
Estradiol, pg/mL       
    Linear modelc −0.03264 0.04     
    Polynomial modeld 0.05917 0.10 −0.02724 0.004 8.55 0.0002 
Bioavailable estradiol, pg/mL       
    Linear modelc −0.07197 0.01     
    Polynomial modeld 0.08409 0.21 −0.04466 0.01 6.96 0.001 
Free estradiol, pg/mL       
    Linear modelc −0.06346 0.001     
    Polynomial modeld 0.02421 0.58 −0.02515 0.03 4.99 0.007 
Estrone, pg/mL       
    Linear modelc −0.01233 0.45     
    Polynomial modeld 0.08243 0.03 −0.0276 0.005 8.21 0.0003 
Estrone sulfate, pg/mL       
    Linear modelc −0.02312 0.26     
    Polynomial modeld 0.03107 0.51 −0.01564 0.20 1.62 0.20 
Androstenedione, ng/dL       
    Linear modelc −0.01852 0.29     
    Polynomial modeld 0.07898 0.05 −0.02844 0.006 7.72 0.0004 
Testosterone, ng/dL       
    Linear modelc −0.01282 0.43     
    Polynomial modeld 0.03697 0.32 −0.01454 0.14 2.29 0.11 
DHEA, ng/dL       
    Linear modelc 0.01784 0.41     
    Polynomial modeld 0.13066 0.007 −0.03331 0.009 7.07 0.0009 
DHEAS, μg/dL       
    Linear modelc 0.01664 0.45     
    Polynomial modeld 0.0908 0.07 −0.02144 0.10 2.71 0.07 
SHBG, nmol/L       
    Linear modelc 0.04508 0.007     
    Polynomial modeld −0.03848 0.29 0.02478 0.01 6.82 0.001 

Abbreviations: DHEA, dehydroepiandosterone; DHEAS, dehydroepiandosterone sulfate; MET, metabolic equivalent; SHBG, sex hormone-binding globulin.

a

Hormone levels were adjusted age, batch, time of blood collection, fasting status, age at menarche, parity × age at first birth, age at menopause, smoking status, history of tubal ligation, history of bilateral oophorectomy, and alcohol intake.

b

All P values are 2-sided.

c

Linear model: y = α + β1 (ln MET-hours per week) + covariates listed in footnote a.

d

Polynomial model: y = α + β1 (ln MET-hours per week) + β2 (ln MET hours per week)2 + covariates listed in footnote a.

We stratified our population by BMI (<23, 23−<27, ≥27 kg/m2) at the time of blood collection. Median MET-hours per week in quintile 1 and quintile 5 were relatively similar across the 3 levels of BMI (BMI <23: median of quintile 1 = 1.7 MET-hours per week, quintile 5 = 35.2; BMI 23–<27: quintile 1 = 1.5, quintile 5 = 34.1; and BMI ≥27: quintile 1 = 1.7, quintile 5 = 29.9). In leaner women (BMI <23 kg/m2), estradiol, estrone, and estrone sulfate levels were lowest in those in quintile 1 and quintile 5 of MET-hours per week compared with those in the middle quintiles (results not shown). For example, estradiol levels across the 5 quintiles were 4.7, 6.1, 5.2, 5.6, and 4.5 pg/mL, respectively. Androgen levels also demonstrated a similar pattern in leaner women; for example, androstenedione levels across quintiles 1–5 were 66, 100, 75, 70, and 56 ng/dL, respectively. We did not observe consistent associations between physical activity and steroid hormone levels in moderate-weight and heavier women. Results also tended to be stronger for women reporting any weight loss between 1988 and date of blood draw than for those reporting no change in weight or weight gain. We did not find change in physical activity level between 1988 and 1992 to be related to hormone levels (results not shown).

Results from secondary analyses using physical activity levels reported in 1988 only, average of 1988 and 1992, average activity in 1988–1992 stratified by change in activity, and analyses restricted to women without prior oophorectomy were similar to those from the main analysis (results not shown). Results evaluating hormone levels over deciles of physical activity were also similar (results not shown).

DISCUSSION

Although we observed some evidence of a linear association of estrogen and SHBG levels with recreational physical activity in postmenopausal women, for several hormones, the relation with activity appeared nonlinear. Levels of several hormones were 10%–15% lower in the least and most active women than in those reporting moderate activity. This pattern was reversed for SHBG: levels were higher in women in the extreme quintiles of activity compared with those in the middle categories. For estradiol, estrone, DHEA, androstenedione, and SHBG, results from regression analyses indicated that adding a second-order term significantly improved model fit.

A limited number of studies have assessed these associations, with inconsistent results. In several studies, levels of estrone, estradiol, testosterone, and/or androstenedione have been inversely associated with physical activity (26, 27, 32, 33, 35). However, in one study, estradiol levels were significantly higher in women regularly engaging in vigorous activity compared with less-active women (30). Wu et al. (31) observed a significant inverse correlation between physical activity and SHBG levels (r = −0.24; P < 0.05), while others have found either no relation (30) or a positive association (26, 35).

In a randomized trial, McTiernan et al. (28) observed greater decreases in estrone and free estradiol levels in women assigned to a physical activity intervention than in controls and modest increases in SHBG levels. In the intervention group, estrone, estradiol, and free estradiol decreased by a greater proportion in women losing body fat than in those not changing or gaining body fat during the intervention. Androgen levels did not differ significantly between groups (29), but they decreased by a greater proportion in exercisers losing body fat. These findings underscore the importance of evaluating these associations in the context of BMI and/or weight change.

Most recently, van Gils et al. (35) evaluated sex steroid hormone levels adjusted and nonadjusted for BMI. As in our study, unadjusted results suggested a linear inverse relation between activity and estradiol and positive associations with DHEAS and SHBG. However, after adjustment for BMI, linear associations were attenuated, and, for several hormones—including estrone, estradiol, and testosterone—mean levels were highest in women reporting moderate activity compared with both active and inactive women. Potential U-shaped associations between hormones and activity have been suggested in other studies (32, 33), but, to our knowledge, no other studies have formally tested for nonlinearity.

Our results suggest that many postmenopausal women who engage in light-moderate recreational activity may in fact have higher estrogen and perhaps androgen levels than sedentary women. It is also possible that relatively few older women exercise frequently or intensely enough to lower hormone levels below those of sedentary women. If higher estrogen and androgen levels do indeed increase the risk of ovarian cancer, this factor may help explain results from recent analyses suggesting that frequent vigorous activity in postmenopausal women may increase risk (18–20).

For example, in our population, ovarian cancer risk was somewhat higher for women reporting moderate-vigorous activity compared with sedentary women (19). Similar results were observed in the Iowa Women's Health Study (18, 20). In other studies (11–13, 15, 16), a lower risk of ovarian cancer was associated with only the highest levels of activity. In studies with small numbers of cases, such as many ovarian cancer studies, the range of activity that can be assessed may be small and the level of activity in the top category may be relatively low; protective effects of activity on cancer risk may be observable at higher levels only. This may not be a problem in studies of breast and endometrial cancer, which tend to include more cases and thus have sufficient statistical power to evaluate the effects of higher levels of activity. However, the associations of sex steroid hormones with ovarian cancer remain unclear (47). Whereas one study found circulating androgen and estrogen levels to be positively associated with ovarian cancer risk (25), others have not observed associations between risk and androgen levels (48–50). Additional studies exploring the role of physical activity and hormones in ovarian cancer etiology are needed.

One limitation of our study concerns the timing of activity assessment versus hormone measurement. Blood collection took place 1–2 years after activity assessment in 1988. Changes in activity level between 1988 and blood collection could have resulted in misclassification of activity and limited our ability to assess this relation, especially if changes in activity have an immediate effect on hormone levels, as suggested by McTiernan et al. (28, 29). To help limit misclassification, we averaged physical activity participation in 1986 and 1988 instead of assessing one time period only. MET-hours of activity reported in 1986 and 1988 were highly correlated (r = 0.67; P < 0.0001), as were levels in 1988 and 1992 (r = 0.50; P < 0.0001), suggesting that activity levels in our population remained fairly consistent over time. Furthermore, results based on activity in 1988 and the average of 1988 and 1992 were similar to those from the main analysis. We did not find change in activity between 1988 and 1992 related to hormone levels. It should be recognized that our assessment of physical activity was based on self-report of the most common types of recreational activity practiced by our participants and did not consider occupational and household activities. Finally, results may not be generalizable to women of color because our study population was nearly all white, although it is unlikely that ethnicity alters the physiologic relation between activity and steroid hormone levels.

In conclusion, results from our study suggest that recreational physical activity may not be linearly related to postmenopausal steroid hormone levels. Estrogen and androgen levels may be lowest in women reporting high activity levels, and perhaps also in sedentary women, and highest in women reporting moderate activity. Additional randomized trials in which the effects of intense physical activity on hormone levels in lean, moderate, and heavier women are assessed are needed to further clarify these associations.

Abbreviations

    Abbreviations
  • BMI

    body mass index

  • DHEA(S)

    dehydroepiandosterone (sulfate)

  • MET

    metabolic equivalent

  • SHBG

    sex hormone-binding globulin

Author affiliations: Department of Public Health, University of Massachusetts, Amherst, Massachusetts (Elizabeth R. Bertone-Johnson); Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Shelley S. Tworoger, Susan E. Hankinson); and Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts (Shelley S. Tworoger, Susan E. Hankinson).

This work was supported by Public Health Services grants CA49449 and CA87969 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

Conflict of interest: none declared.

References

1.
Sprague
BL
Trentham-Dietz
A
Newcomb
PA
, et al.  . 
Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer
Cancer Epidemiol Biomarkers Prev
 , 
2007
, vol. 
16
 
2
(pg. 
236
-
243
)
2.
Monninkhof
EM
Elias
SG
Vlems
FA
, et al.  . 
Physical activity and breast cancer: a systematic review
Epidemiology
 , 
2007
, vol. 
18
 
1
(pg. 
135
-
157
)
3.
Bernstein
L
Patel
AV
Ursin
G
, et al.  . 
Lifetime recreational exercise activity and breast cancer risk among black women and white women
J Natl Cancer Inst
 , 
2005
, vol. 
97
 
22
(pg. 
1671
-
1679
)
4.
McTiernan
A
Kooperberg
C
White
E
, et al.  . 
Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study
JAMA
 , 
2003
, vol. 
290
 
10
(pg. 
1331
-
1336
)
5.
Patel
AV
Calle
EE
Bernstein
L
, et al.  . 
Recreational physical activity and risk of postmenopausal breast cancer in a large cohort of US women
Cancer Causes Control
 , 
2003
, vol. 
14
 
6
(pg. 
519
-
529
)
6.
Rockhill
B
Willett
WC
Hunter
DJ
, et al.  . 
A prospective study of recreational physical activity and breast cancer risk
Arch Intern Med
 , 
1999
, vol. 
159
 
19
(pg. 
2290
-
2296
)
7.
Voskuil
DW
Monninkhof
EM
Elias
SG
, et al.  . 
Physical activity and endometrial cancer risk, a systematic review of current evidence
Cancer Epidemiol Biomarkers Prev
 , 
2007
, vol. 
16
 
4
(pg. 
639
-
648
)
8.
Matthews
CE
Xu
WH
Zheng
W
, et al.  . 
Physical activity and risk of endometrial cancer: a report from the Shanghai Endometrial Cancer Study
Cancer Epidemiol Biomarkers Prev
 , 
2005
, vol. 
14
 
4
(pg. 
779
-
785
)
9.
Moradi
T
Weiderpass
E
Signorello
LB
, et al.  . 
Physical activity and postmenopausal endometrial cancer risk (Sweden)
Cancer Causes Control
 , 
2000
, vol. 
11
 
9
(pg. 
829
-
837
)
10.
Olsen
CM
Bain
CJ
Jordan
SJ
, et al.  . 
Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis
Cancer Epidemiol Biomarkers Prev
 , 
2007
, vol. 
16
 
11
(pg. 
2321
-
2330
)
11.
Biesma
RG
Schouten
LJ
Dirx
MJ
, et al.  . 
Physical activity and risk of ovarian cancer: results from the Netherlands Cohort Study (The Netherlands)
Cancer Causes Control
 , 
2006
, vol. 
17
 
1
(pg. 
109
-
115
)
12.
Patel
AV
Rodriguez
C
Pavluck
AL
, et al.  . 
Recreational physical activity and sedentary behavior in relation to ovarian cancer risk in a large cohort of US women
Am J Epidemiol
 , 
2006
, vol. 
163
 
8
(pg. 
709
-
716
)
13.
Pan
SY
Ugnat
AM
Mao
Y
Physical activity and the risk of ovarian cancer: a case-control study in Canada
Int J Cancer
 , 
2005
, vol. 
117
 
2
(pg. 
300
-
307
)
14.
Schnohr
P
Grønbaek
M
Petersen
L
, et al.  . 
Physical activity in leisure-time and risk of cancer: 14-year follow-up of 28,000 Danish men and women
Scand J Public Health
 , 
2005
, vol. 
33
 
4
(pg. 
244
-
249
)
15.
Bertone
ER
Newcomb
PA
Willett
WC
, et al.  . 
Recreational physical activity and ovarian cancer in a population-based case-control study
Int J Cancer
 , 
2002
, vol. 
99
 
3
(pg. 
431
-
436
)
16.
Cottreau
CM
Ness
RB
Kriska
AM
Physical activity and reduced risk of ovarian cancer
Obstet Gynecol
 , 
2000
, vol. 
96
 
4
(pg. 
609
-
614
)
17.
Riman
T
Dickman
PW
Nilsson
S
, et al.  . 
Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women
Eur J Epidemiol
 , 
2004
, vol. 
19
 
11
(pg. 
1011
-
1019
)
18.
Anderson
JP
Ross
JA
Folsom
AR
Anthropometric variables, physical activity and incidence of ovarian cancer. The Iowa Women's Health Study
Cancer
 , 
2004
, vol. 
100
 
7
(pg. 
1515
-
1521
)
19.
Bertone
ER
Willett
WC
Rosner
BA
, et al.  . 
Prospective study of recreational physical activity and ovarian cancer
J Natl Cancer Inst
 , 
2001
, vol. 
93
 
12
(pg. 
942
-
948
)
20.
Mink
PJ
Folsom
AR
Sellers
TA
, et al.  . 
Physical activity, waist-to-hip ratio, and other risk factors for ovarian cancer: a follow-up study of older women
Epidemiology
 , 
1996
, vol. 
7
 
1
(pg. 
38
-
45
)
21.
Friedenreich
CM
Orenstein
MR
Physical activity and cancer prevention: etiologic evidence and biological mechanisms
J Nutr
 , 
2002
, vol. 
132
 
11 suppl
(pg. 
3456S
-
3464S
)
22.
Missmer
SA
Eliassen
AH
Barbieri
RL
, et al.  . 
Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women
J Natl Cancer Inst
 , 
2004
, vol. 
96
 
24
(pg. 
1856
-
1865
)
23.
Key
T
Appleby
P
Barnes
I
, et al.  . 
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies
J Natl Cancer Inst
 , 
2002
, vol. 
94
 
8
(pg. 
606
-
616
)
24.
Risch
HA
Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone
J Natl Cancer Inst
 , 
1998
, vol. 
90
 
23
(pg. 
1774
-
1786
)
25.
Helzlsouer
KJ
Alberg
AJ
Gordon
GB
, et al.  . 
Serum gonadotropins and steroid hormones and the development of ovarian cancer
JAMA
 , 
1995
, vol. 
274
 
24
(pg. 
1926
-
1930
)
26.
Chan
MF
Dowsett
M
Folkerd
E
, et al.  . 
Usual physical activity and endogenous sex hormones in postmenopausal women: the European Prospective Investigation into Cancer-Norfolk Population Study
Cancer Epidemiol Biomarkers Prev
 , 
2007
, vol. 
16
 
5
(pg. 
900
-
905
)
27.
McTiernan
A
Wu
L
Chen
C
, et al.  . 
Relation of BMI and physical activity to sex hormones in postmenopausal women
Obesity (Silver Spring)
 , 
2006
, vol. 
14
 
9
(pg. 
1662
-
1677
)
28.
McTiernan
A
Tworoger
SS
Ulrich
CM
, et al.  . 
Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial
Cancer Res.
 , 
2004
, vol. 
64
 
8
(pg. 
2923
-
2928
)
29.
McTiernan
A
Tworoger
SS
Rajan
KB
, et al.  . 
Effect of exercise on serum androgens in postmenopausal women: a 12-month randomized clinical trial
Cancer Epidemiol Biomarkers Prev
 , 
2004
, vol. 
13
 
7
(pg. 
1099
-
1105
)
30.
Verkasalo
PK
Thomas
HV
Appleby
PN
, et al.  . 
Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom)
Cancer Causes Control
 , 
2001
, vol. 
12
 
1
(pg. 
47
-
59
)
31.
Wu
F
Ames
R
Evans
MC
, et al.  . 
Determinants of sex hormone-binding globulin in normal postmenopausal women
Clin Endocrinol (Oxf)
 , 
2001
, vol. 
54
 
1
(pg. 
81
-
87
)
32.
Madigan
MP
Troisi
R
Potischman
N
, et al.  . 
Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States)
Cancer Causes Control
 , 
1998
, vol. 
9
 
2
(pg. 
199
-
207
)
33.
Cauley
JA
Gutai
JP
Kuller
LH
, et al.  . 
The epidemiology of serum sex hormones in postmenopausal women
Am J Epidemiol
 , 
1989
, vol. 
129
 
6
(pg. 
1120
-
1131
)
34.
Schmitz
KH
Lin
H
Sammel
MD
, et al.  . 
Association of physical activity with reproductive hormones: the Penn Ovarian Aging Study
Cancer Epidemiol Biomarkers Prev
 , 
2007
, vol. 
16
 
10
(pg. 
2042
-
2047
)
35.
van Gils
CH
Peeters
PH
Schoenmakers
MC
, et al.  . 
Physical activity and endogenous sex hormone levels in postmenopausal women: a cross-sectional study in the Prospect-EPIC Cohort
Cancer Epidemiol Biomarkers Prev
 , 
2009
, vol. 
18
 
2
(pg. 
377
-
383
)
36.
Hankinson
SE
Willett
WC
Manson
JE
, et al.  . 
Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women
J Natl Cancer Inst
 , 
1995
, vol. 
87
 
17
(pg. 
1297
-
1302
)
37.
Hankinson
SE
Willett
WC
Manson
JE
, et al.  . 
Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
J Natl Cancer Inst
 , 
1998
, vol. 
90
 
17
(pg. 
1292
-
1299
)
38.
Wolf
AM
Hunter
DJ
Colditz
GA
, et al.  . 
Reproducibility and validity of a self-administered physical activity questionnaire
Int J Epidemiol
 , 
1994
, vol. 
23
 
5
(pg. 
991
-
999
)
39.
Ainsworth
BE
Haskell
WL
Leon
AS
, et al.  . 
Compendium of physical activities: classification of energy costs of human physical activities
Med Sci Sports Exerc
 , 
1993
, vol. 
25
 
1
(pg. 
71
-
80
)
40.
Abraham
GE
Tulchinsky
D
Korenman
SG
Chromatographic purification of estradiol-17 for use in radio-ligand assay
Biochem Med
 , 
1970
, vol. 
3
 
5
(pg. 
365
-
368
)
41.
Mikhail
G
Chung
HW
Peron
FG
Caldwells
BV
Radioimmunoassay of plasma estrogens. Use of polymerized antibodies
Immunological Methods in Steroid Determination
 , 
1970
New York, NY
Appleton-Century-Croft
pg. 
113
 
42.
Mikhail
G
Wu
CH
Ferin
M
, et al.  . 
Radioimmunoassay of plasma estrone and estradiol
Steroids
 , 
1970
, vol. 
15
 
3
(pg. 
333
-
352
)
43.
Kinouchi
T
Pages
L
Horton
R
A specific radioimmunoassay for testosterone in peripheral plasma
J Lab Clin Med
 , 
1973
, vol. 
82
 
2
(pg. 
309
-
316
)
44.
McNatty
KP
Smith
DM
Makris
A
, et al.  . 
The microenvironment of the human antral follicle: interrelationships among the steroid levels in antral fluid, the population of granulosa cells, and the status of the oocyte in vivo and in vitro
J Clin Endocrinol Metab
 , 
1979
, vol. 
49
 
6
(pg. 
851
-
860
)
45.
Buster
JE
Abraham
GE
Radioimmunoassay of serum DHEAS
Analytic Lett.
 , 
1972
pg. 
543
 
46.
Franz
C
Watson
D
Longcope
C
Estrone sulfate and dehydroepiandrosterone sulfate concentrations in normal subjects and men with cirrhosis
Steroids
 , 
1979
, vol. 
34
 
5
(pg. 
563
-
573
)
47.
Lukanova
A
Kaaks
R
Endogenous hormones and ovarian cancer: epidemiology and current hypotheses
Cancer Epidemiol Biomarkers Prev
 , 
2005
, vol. 
14
 
1
(pg. 
98
-
107
)
48.
Tworoger
SS
Lee
IM
Buring
JE
, et al.  . 
Plasma androgen concentrations and risk of incident ovarian cancer
Am J Epidemiol
 , 
2008
, vol. 
167
 
2
(pg. 
211
-
218
)
49.
Rinaldi
S
Dossus
L
Lukanova
A
, et al.  . 
Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)
Cancer Epidemiol Biomarkers Prev
 , 
2007
, vol. 
16
 
1
(pg. 
23
-
29
)
50.
Lukanova
A
Lundin
E
Akhmedkhanov
A
, et al.  . 
Circulating levels of sex steroid hormones and risk of ovarian cancer
Int J Cancer
 , 
2003
, vol. 
104
 
5
(pg. 
636
-
642
)